A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects

Trial Profile

A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2015

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Fosdevirine (Primary)
  • Indications Pregnancy; Viral infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 05 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 May 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 09 Feb 2011 The development program for IDX 899 has been placed on clinical hold by the FDA, according to an Idenix Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top